Skip Navigation

JNCI Journal of the National Cancer Institute 2000 92(5):368-369; doi:10.1093/jnci/92.5.368
© 2000 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Illman, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Illman, J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 92, No. 5, 368-369, March 1, 2000
© 2000 Oxford University Press

NEWS

Britain Debates Validity Of Guideline Development

John Illman

Britain’s National Institute for Clinical Excellence (NICE) is being hailed as a potential solution to perceived problems of care rationing, poor medical practice, and the absence of a sensible mechanism to introduce new drugs under the nation’s health care system.

The chair, Sir Michael Rawlins, M.D., a clinical pharmacologist, said NICE will issue treatment guidelines he hopes will supersede those that, he says, are "bewildering in number, uncertain in content, difficult to access, and very often totally indigestible." NICE, established by the government to evaluate new technologies and issue guidelines, intends to prevent long delays in . . . [Full Text of this Article]

Conclusions Based on Science


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?